Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Teva Pharmaceutical Industries ( TEVA) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.3%. By the end of trading, Teva Pharmaceutical Industries rose $0.94 (1.9%) to $50.85 on light volume. Throughout the day, 4,754,992 shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 7,285,400 shares. The stock ranged in a price between $50.04-$50.97 after having opened the day at $50.14 as compared to the previous trading day's close of $49.91. Other companies within the Drugs industry that increased today were: Retrophin ( RTRX), up 17.9%, Galectin Therapeutics ( GALT), up 12.9%, Evoke Pharma ( EVOK), up 11.3% and Sorrento Therapeutics ( SRNE), up 9.3%.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $47.0 billion and is part of the health care sector. Shares are up 24.5% year to date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Rockwell Medical ( RMTI), down 6.7%, Tekmira Pharmaceuticals Corporation ( TKMR), down 6.7%, China Pharma ( CPHI), down 6.3% and OxiGene ( OXGN), down 6.0% , were all laggards within the drugs industry with Questcor Pharmaceuticals ( QCOR) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern

Jim Cramer: Centene Is in All the Big Medicare Markets

Jim Cramer: Centene Is in All the Big Medicare Markets

Jim Cramer on the Markets: I Struggle With How Negative Things Are

Jim Cramer on the Markets: I Struggle With How Negative Things Are

Video: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene